trial

Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics

NCTId NCT01811160
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 50 (actual)
Sponsored by Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Primary completion 2011-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-10
Primary completion
2011-11
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Melatonin

Sponsors

Instituto Nacional de Psiquiatría Dr. Ramón de la FuenteLead Sponsor

Investigators

1
Francisco Romo-Nava, MDPrincipal Investigator

Sites

1 total
Mexico City, Mexico

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE4
Primary Completion Date
2011-11
Status
COMPLETED
relationships
The graph out of here
drug
Melatonin
drug
lead_sponsor
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
company
indication
Bipolar Disorder
indication
Schizophrenia
indication
Second Generation Antipsychotic Induced Metabolic Adverse Effects
indication
investigator
Francisco Romo-Nava, MD
person